These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

867 related items for PubMed ID: 29525970

  • 41. Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials.
    Lee YH, Song GG.
    Korean J Intern Med; 2011 Sep; 26(3):340-7. PubMed ID: 22016595
    [Abstract] [Full Text] [Related]

  • 42. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
    Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, Krege JH.
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3772-80. PubMed ID: 19584192
    [Abstract] [Full Text] [Related]

  • 43. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
    Fitzpatrick LA, Dabrowski CE, Cicconetti G, Gordon DN, Papapoulos S, Bone HG, Bilezikian JP.
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2441-9. PubMed ID: 21593114
    [Abstract] [Full Text] [Related]

  • 44. The challenge of long-term adherence: The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis.
    Fontalis A, Eastell R.
    Bone; 2020 Jul; 136():115336. PubMed ID: 32234415
    [Abstract] [Full Text] [Related]

  • 45. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
    Xu XJ, Ma DD, Lv F, Wang JY, Liu Y, Xia WB, Jiang Y, Wang O, Xing XP, Yu W, Li M.
    Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615
    [Abstract] [Full Text] [Related]

  • 46. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women.
    Stock JL, Bell NH, Chesnut CH, Ensrud KE, Genant HK, Harris ST, McClung MR, Singer FR, Yood RA, Pryor-Tillotson S, Wei L, Santora AC.
    Am J Med; 1997 Oct; 103(4):291-7. PubMed ID: 9382121
    [Abstract] [Full Text] [Related]

  • 47. Evaluation of bone remodelling parameters after one year treatment with alendronate in postmenopausal women with osteoporosis.
    Kučukalić-Selimović E, Valjevac A, Hadžović-Džuvo A, Skopljak-Beganović A, Alimanovic-Alagić R, Brković A.
    Bosn J Basic Med Sci; 2011 Feb; 11(1):41-5. PubMed ID: 21342141
    [Abstract] [Full Text] [Related]

  • 48. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
    Hiligsmann M, Reginster JY.
    Osteoporos Int; 2019 Mar; 30(3):649-658. PubMed ID: 30701342
    [Abstract] [Full Text] [Related]

  • 49. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial.
    McClung MR, Lewiecki EM, Geller ML, Bolognese MA, Peacock M, Weinstein RL, Ding B, Rockabrand E, Wagman RB, Miller PD.
    Osteoporos Int; 2013 Jan; 24(1):227-35. PubMed ID: 22776860
    [Abstract] [Full Text] [Related]

  • 50. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
    Bonnick S, Broy S, Kaiser F, Teutsch C, Rosenberg E, DeLucca P, Melton M.
    Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
    [Abstract] [Full Text] [Related]

  • 51. Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
    McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S, Delmas P.
    Osteoporos Int; 2013 Jan; 24(1):293-9. PubMed ID: 22752050
    [Abstract] [Full Text] [Related]

  • 52. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 53. Effectiveness of monthly intravenous ibandronate on the low responders to oral bisphosphonate: the MOVEMENT study.
    Hagino H, Sakai A, Ikeda S, Imanishi Y, Tsurukami H, Nakajo S, Miyakoshi N.
    J Bone Miner Metab; 2019 Nov; 37(6):1013-1023. PubMed ID: 31098670
    [Abstract] [Full Text] [Related]

  • 54. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
    Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E.
    J Clin Endocrinol Metab; 2002 Mar; 87(3):985-92. PubMed ID: 11889149
    [Abstract] [Full Text] [Related]

  • 55. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P.
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [Abstract] [Full Text] [Related]

  • 56. Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China.
    Liao EY, Zhang ZL, Xia WB, Lin H, Cheng Q, Wang L, Hao YQ, Chen DC, Tang H, Peng YD, You L, He L, Hu ZH, Song CL, Wei F, Wang J, Zhang L.
    Medicine (Baltimore); 2018 Aug; 97(31):e11694. PubMed ID: 30075569
    [Abstract] [Full Text] [Related]

  • 57. Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis.
    Koldkjær Sølling AS, Harsløf T, Langdahl B.
    Osteoporos Int; 2019 May; 30(5):995-1002. PubMed ID: 30656367
    [Abstract] [Full Text] [Related]

  • 58. Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: a post hoc subgroup analysis of a phase III trial in Japan.
    Sugimoto T, Inoue D, Maehara M, Oikawa I, Shigematsu T, Nishizawa Y.
    J Bone Miner Metab; 2019 Jul; 37(4):730-740. PubMed ID: 30523414
    [Abstract] [Full Text] [Related]

  • 59. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A, Hawkins F, Micaelo M, Minisola S, Papaioannou N, Stone M, Ferreira I, Siddhanti S, Wagman RB, Brown JP.
    Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
    [Abstract] [Full Text] [Related]

  • 60. Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet.
    McClung MR, Miller PD, Brown JP, Zanchetta J, Bolognese MA, Benhamou CL, Balske A, Burgio DE, Sarley J, McCullough LK, Recker RR.
    Osteoporos Int; 2012 Jan; 23(1):267-76. PubMed ID: 21947137
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 44.